Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats
Open Access
- 11 February 2015
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 11 (6), 4190-4196
- https://doi.org/10.3892/mmr.2015.3333
Abstract
Idiopathic pulmonary fibrosis is a chronic and progressive fibrotic lung disorder with unknown etiology and a high mortality rate. Tanshinone ⅡA (Tan ⅡA) is a lipophilic diterpene extracted from the Chinese herb Salvia miltiorrhiza Bunge with diverse biological functions. The present study was conducted to evaluate the effects of Tan ⅡA on bleomycin (BLM)‑induced pulmonary fibrosis in rats. Rats received an intraperitoneal injection of Tan ⅡA and normal rats were used as controls. Severe pulmonary edema, inflammation and fibrosis were observed in the BLM‑treated rats and the counts of total cells, neutrophils and lymphocytes were significantly increased in the bronchoalveolar lavage fluids of those rats. These pathological changes were markedly attenuated by subsequent treatment with Tan ⅡA. In addition, BLM‑induced increased expression of tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6, cyclooxygenase‑2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan ⅡA injection. The present findings suggest therapeutic potential of Tan ⅡA for pulmonary fibrosis.Keywords
This publication has 45 references indexed in Scilit:
- Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activationCell Death & Disease, 2013
- Molecular and cellular mechanisms of pulmonary fibrosisFibrogenesis & Tissue Repair, 2012
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Neuroprotection of Tanshinone IIA against Cerebral Ischemia/Reperfusion Injury through Inhibition of Macrophage Migration Inhibitory Factor in RatsPLOS ONE, 2012
- Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathyCardiovascular Diabetology, 2011
- Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosisExperimental & Molecular Medicine, 2010
- Balance point characterization of interstitial fluid volume regulationAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Pulmonary fibrosis: pathogenesis, etiology and regulationMucosal Immunology, 2009
- First drug for idiopathic pulmonary fibrosis approved in JapanNature Reviews Drug Discovery, 2008
- The Role of Inflammation in the Pathogenesis of Idiopathic Pulmonary FibrosisAntioxidants and Redox Signaling, 2008